Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?

Affiliations

¹ Center for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
² Surgical Oncology, Maine Medical Center Cancer Institute, Scarborough, Maine, USA.
³ Department of Radiation Oncology, University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.

Editorial

Jimmy T Efird et al. Transl Gastroenterol Hepatol. 2018.

. 2018 Sep 7:3:58.

doi: 10.21037/tgh.2018.08.06. eCollection 2018.

¹ Center for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
² Surgical Oncology, Maine Medical Center Cancer Institute, Scarborough, Maine, USA.
³ Department of Radiation Oncology, University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D. Shah MA, et al. JAMA Oncol. 2017 May 1;3(5):620-627. doi: 10.1001/jamaoncol.2016.5580. JAMA Oncol. 2017. PMID: 27918764 Free PMC article. Clinical Trial.

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30. 10.3322/caac.21387 - DOI - PubMed
1. Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. 10.2147/CMAR.S149619 - DOI - PMC - PubMed
1. Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget 2017;8:57654-69. 10.18632/oncotarget.14825 - DOI - PMC - PubMed
1. Shah MA, Bang YJ, Lordick F, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol 2017;3:620-7. 10.1001/jamaoncol.2016.5580 - DOI - PMC - PubMed
1. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013;110:E2987-96. 10.1073/pnas.1302725110 - DOI - PMC - PubMed